Longer Treatment For Children With Langerhans Cell Hystiocytosis Improves Survival Rates
A new international study finds that prolonged, intense initial treatment in children with multi-system Langerhans cell histiocytosis (MS-LCH) can achieve survival rates as high as 84 percent - a full 15 percent improvement over the previous clinical trial in this series. The study, LCH-III, is published in Blood, the journal of the American Society of Hematology. It is the third in a series of international randomized clinical trials for LCH that spans twenty years initiated and coordinated by the Histiocyte Society, a group of more than 200 physicians and scientists worldwide...
Publication date: Available online 6 April 2020Source: Journal of Geriatric OncologyAuthor(s): Heidi D. Klepin, Nina Rosa Neuendorff, Richard A. Larson, Marije E. Hamaker, Massimo Breccia, Pau Montesinos, Raul Cordoba
Objective The study is to investigate the application of 18F-fluorodeoxyglucose (18F-FDG) PET/computerized tomography (CT) for the evaluation of mantle cell lymphoma (MCL). Methods We retrospectively analyzed 39 patients who were pathologically diagnosed with MCL and underwent 18F-FDG PET/CT before treatment between August 2007 and August 2018. We compared the clinical information and PET/CT imaging characteristics in different groups based on bone marrow invasion, spleen invasion or International Prognostic Index (IPI) score. We also assessed the efficacy of PET/CT evaluation basing on the follow-up PET CT findings o...
A single infusion of a new form of CAR T-cell therapy induces durable remissions in relapsed/refractory mantle cell lymphoma following BKT failure.Medscape Medical News
Publication date: Available online 6 April 2020Source: Life SciencesAuthor(s): Marwa Houssein, Maamoun Fatfat, Zeina Habli, Nasab Ghazal, Sara Mokdad, Hala Khalife, Mahmoud Khalil, Hala Gali-Muhtasib
Publication date: Available online 6 April 2020Source: Medical Mycology Case ReportsAuthor(s): Rita Filipe, João Paulo Caldas, Neuza Soares, Raquel Sabino, Cristina Veríssimo, Roberto Silva, André Silva-Pinto, Margarida Tavares, António Sarmento
Condition: Leukemia Intervention: Biological: IM19 CAR-T Sponsor: Beijing Immunochina Medical Science&Technology Co., Ltd. Recruiting
Condition: Leukemia, Myeloid, Acute Intervention: Drug: Gemtuzumab Ozogamicin Sponsor: Pfizer Not yet recruiting
Condition: Leukemia, Myeloid, Acute Interventions: Drug: CC-90009; Drug: Venetoclax; Drug: Azacitidine; Drug: Gilteritinib Sponsors: Celgene; AbbVie Not yet recruiting
Abstract Hematologic neoplasms that primarily present in bone are rare; this article describes the most common examples of hematologic tumors primarily presenting in bone, including plasma cell myeloma, solitary plasmacytoma of bone, primary non-Hodgkin lymphoma of bone, acute lymphoblastic leukemia/lymphoma, and Langerhans cell histiocytosis. The macroscopic and microscopic features, differential diagnosis, diagnostic workup, and prognosis of all these different entities are discussed, with special emphasis on common differential diagnosis. PMID: 28797508 [PubMed - in process]
Plasma cell myeloma is the most common primary malignant bone neoplasm and diffuse large B-cell lymphoma is the most frequent type of non-Hodgkin lymphoma primarily presenting in bone. Because clinical and morphologic features may overlap between primary malignant hematologic tumors in bone and other malignant tumors, as well as benign proliferations, a final diagnosis in bone lesions can be challenging. We discuss the differential diagnosis of plasma cell myeloma, solitary plasmacytoma of bone, primary non-Hodgkin lymphoma of bone, acute lymphoblastic leukemia/lymphoma, and Langerhans cell histiocytosis.